Hyphens Pharma International Limited
Hyphens Pharma International Limited, often referred to as Hyphens Pharma, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Singapore (SG). Established in 2001, the company has made significant strides in providing innovative healthcare solutions across Asia, with a focus on specialty pharmaceuticals and consumer health products. Hyphens Pharma is renowned for its unique portfolio, which includes prescription medicines, over-the-counter products, and nutraceuticals. The company distinguishes itself through strategic partnerships and a commitment to quality, ensuring that its offerings meet the highest standards of efficacy and safety. With a strong market position, Hyphens Pharma has achieved notable milestones, including expanding its operational reach and enhancing its product line to cater to diverse healthcare needs.
DitchCarbon Score
How does Hyphens Pharma International Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hyphens Pharma International Limited's score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hyphens Pharma International Limited's reported carbon emissions
In 2024, Hyphens Pharma International Limited reported total carbon emissions of approximately 470,200 kg CO2e, comprising 26,200 kg CO2e from Scope 1 and 444,000 kg CO2e from Scope 2 emissions. This marks an increase from 2023, where the company recorded total emissions of about 408,700 kg CO2e, with 10,700 kg CO2e from Scope 1 and 398,000 kg CO2e from Scope 2. Hyphens Pharma has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi). The company’s emissions data is self-reported and does not cascade from a parent organization, indicating that their climate commitments and performance are independently managed. The GHG emissions intensity for both years stands at approximately 0.0024 tCO2e per million USD in revenue, reflecting their operational efficiency in relation to revenue generation. As of now, Hyphens Pharma has not outlined any formal climate pledges or reduction initiatives, positioning them within an industry context that increasingly prioritises sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,700 | 00,000 |
| Scope 2 | 398,000 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hyphens Pharma International Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
